Key Points
- Tenet EVP Thomas Arnst sold 8,000 shares on March 9 at an average price of $238.85 for a total of $1,910,800, leaving him with just 12 shares — a 99.85% reduction in his holdings.
- Strong quarterly results: Tenet posted $4.70 EPS vs. $4.08 expected and $5.53 billion revenue (up 8.9% YoY), and issued FY2026 guidance of 16.190–18.470 EPS.
- Analysts are largely positive, with a consensus rating of “Moderate Buy” and an average price target of $247.67 after several recent upgrades and higher targets from firms like Guggenheim and Barclays.
Tenet Healthcare Corporation (NYSE:THC - Get Free Report) EVP Thomas Arnst sold 8,000 shares of Tenet Healthcare stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $238.85, for a total transaction of $1,910,800.00. Following the transaction, the executive vice president owned 12 shares of the company's stock, valued at $2,866.20. This represents a 99.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Tenet Healthcare Price Performance
Shares of NYSE THC opened at $237.30 on Wednesday. The stock has a market cap of $20.64 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 1.19 and a beta of 1.39. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.68 and a current ratio of 1.76. Tenet Healthcare Corporation has a fifty-two week low of $109.82 and a fifty-two week high of $247.21. The firm's 50-day simple moving average is $211.66 and its 200 day simple moving average is $203.29.
Tenet Healthcare (NYSE:THC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, topping analysts' consensus estimates of $4.08 by $0.62. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The firm had revenue of $5.53 billion during the quarter, compared to analyst estimates of $5.47 billion. During the same period in the previous year, the company posted $3.44 EPS. The company's revenue for the quarter was up 8.9% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. As a group, research analysts anticipate that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.
Institutional Trading of Tenet Healthcare
Several institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC grew its stake in shares of Tenet Healthcare by 6.1% during the first quarter. NewEdge Advisors LLC now owns 2,890 shares of the company's stock valued at $389,000 after buying an additional 166 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Tenet Healthcare by 299.1% during the first quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company's stock valued at $229,000 after acquiring an additional 1,274 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Tenet Healthcare in the second quarter worth about $290,000. Bank of Montreal Can lifted its holdings in Tenet Healthcare by 19.1% in the 2nd quarter. Bank of Montreal Can now owns 31,944 shares of the company's stock worth $5,622,000 after buying an additional 5,128 shares during the period. Finally, Savant Capital LLC grew its position in shares of Tenet Healthcare by 8.8% in the 2nd quarter. Savant Capital LLC now owns 13,247 shares of the company's stock worth $2,331,000 after buying an additional 1,066 shares during the last quarter. Hedge funds and other institutional investors own 95.44% of the company's stock.
Analyst Ratings Changes
A number of research firms have issued reports on THC. Guggenheim lifted their price objective on shares of Tenet Healthcare from $257.00 to $271.00 and gave the stock a "buy" rating in a report on Friday, February 13th. Wall Street Zen upgraded shares of Tenet Healthcare from a "buy" rating to a "strong-buy" rating in a report on Sunday, March 1st. Weiss Ratings upgraded shares of Tenet Healthcare from a "hold (c+)" rating to a "buy (b-)" rating in a report on Monday, December 29th. Barclays lifted their target price on shares of Tenet Healthcare from $240.00 to $257.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Tenet Healthcare in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Tenet Healthcare presently has an average rating of "Moderate Buy" and an average price target of $247.67.
Get Our Latest Report on Tenet Healthcare
Tenet Healthcare Company Profile
(
Get Free Report)
Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.
In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
